ZBIO vs REPL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZBIO · Zenas BioPharma$28.26 ▲ 8.99%
REPL · Replimune$21.62 ▲ 7.99%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZBIO -13.0%
- REPL +148.2%
Head to head
| Metric | ZBIO | REPL |
|---|---|---|
| Price | $28.26 | $21.62 |
| Change today | ▲ 8.99% | ▲ 7.99% |
| Market cap | $1.92B | $2.05B |
| Return, 3 months | -11.7% | +58.2% |
| Return, year to date | -22.2% | +122.4% |
| Return, 1 year | -15.9% | +160.2% |
| P/E (TTM) | – | – |
| P/B | 9.0 | 10.0 |
| P/E percentile vs own 5y | 59th | 35th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -113.4% | +31.3% |
| Gross margin | – | – |
| Operating margin | -27,390.1% | – |
| Net margin | -48,438.4% | – |
| Return on equity | -199.0% | -115.8% |
| Analyst target vs. price | +46.2% | +3.3% |
| Analyst buy share | 67% | 100% |
| RSI (14) | 52 | 80 |
| 30-day volatility | 64.8% | 90.8% |
| Max drawdown, 1 year | -64.8% | -84.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- REPL is the largest of the group by market value.
- REPL has returned the most over the past year.
- ZBIO has been the calmest stock over the last 30 days.